APA (7th ed.) Citation

L, P., R, V., M, M., C, Z., KJ, T., SW, K., . . . JK, S. (2026). Patient-reported outcomes and time to symptomatic progression from PAPILLON: Amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC. Lung cancer (Amsterdam, Netherlands), 213, 108788. https://doi.org/10.1016/j.lungcan.2025.108788

Chicago Style (17th ed.) Citation

L, Paz-Ares, et al. "Patient-reported Outcomes and Time to Symptomatic Progression from PAPILLON: Amivantamab Plus Chemotherapy Vs Chemotherapy as First-line Treatment of EGFR Exon 20 Insertion-mutated Advanced NSCLC." Lung Cancer (Amsterdam, Netherlands) 213 (2026): 108788. https://doi.org/10.1016/j.lungcan.2025.108788.

MLA (9th ed.) Citation

L, Paz-Ares, et al. "Patient-reported Outcomes and Time to Symptomatic Progression from PAPILLON: Amivantamab Plus Chemotherapy Vs Chemotherapy as First-line Treatment of EGFR Exon 20 Insertion-mutated Advanced NSCLC." Lung Cancer (Amsterdam, Netherlands), vol. 213, 2026, p. 108788, https://doi.org/10.1016/j.lungcan.2025.108788.